France Proposes Mediator Injury Compensation Program, Pressuring Servier To Fund It
This article was originally published in The Pink Sheet Daily
Proposal would also shield French regulatory agency that approved the diabetes drug from victims' lawsuits.
You may also be interested in...
If NICE’s backing for Servier’s heart drug Procolaran does spread across Europe, then the resulting returns may offset some of financial pain the French group is set to feel in coming years.
Fees set to be introduced to cover the cost of the European Medicines Agency’s part in improving drug safety could impose a huge burden on the EU pharmaceutical industry and lead to the closure of smaller firms, the industry says.
The European Commission’s allegations against Servier for alleged patent abuses could help to clarify the law in this area for original product manufacturers in the long term.